-
公开(公告)号：WO03031475A8
公开(公告)日：2004-10-14
申请号：PCT/GB0204619
申请日：2002-10-10
Applicant: CELLTECH R&D LTD , POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K16/46 , C12N15/70 , G01N33/577
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565
Abstract: There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
Abstract translation: 公开了含有至少一种衍生自对人KDR具有特异性的小鼠单克隆抗体的CDR的抗体分子。 还公开了CDR移植抗体，其中至少一个CDR是杂交CDR。 进一步公开的是编码抗体分子链，载体，转化的宿主细胞的链DNA序列以及抗体分子用于治疗其中涉及VEGF和/或KDR的疾病的用途。
-
公开(公告)号：IS7173A
公开(公告)日：2004-03-05
申请号：IS7173
申请日：2004-03-05
Applicant: CELLTECH R&D LTD
-
公开(公告)号：ZA200401910B
公开(公告)日：2005-03-09
申请号：ZA200401910
申请日：2004-03-09
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
公开(公告)号：NO20040987L
公开(公告)日：2004-05-10
申请号：NO20040987
申请日：2004-03-08
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C07K16/28 , C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K16/46 , C12N15/70 , G01N33/577
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
公开(公告)号：HU0401618A2
公开(公告)日：2004-11-29
申请号：HU0401618
申请日：2002-10-10
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K16/00
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
Patent Agency Ranking
公开(公告)号：BR0212756A
公开(公告)日：2004-11-16
申请号：BR0212756
申请日：2002-10-10
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K16/46 , C12N15/70 , G01N33/577
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
公开(公告)号：EA010970B1
公开(公告)日：2008-12-30
申请号：EA200400519
申请日：2002-10-10
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C07K16/28 , C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/70 , C12P21/02 , C12P21/08 , G01N33/577
Abstract: Заявленымолекулыантител, содержащиепоменьшеймереодин CDR, полученныйизмышиногомоноклональногоантитела, обладающегоспецифичностьюпоотношениюк KDR человека. Такжезаявлено CDR-привитоеантитело, гдепоменьшеймереодиниз CDR являетсягибридным CDR. Крометого, заявленыпоследовательностиДНК, кодирующиецепимолекулантител, векторы, трансформированныеклетки-хозяеваи применениямолекулантителдлялечениязаболеваний, вкоторыевовлечены VEGF и/или KDR.
-
公开(公告)号：PL370344A1
公开(公告)日：2005-05-16
申请号：PL37034402
申请日：2002-10-10
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K16/46
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
公开(公告)号：NO20040987A
公开(公告)日：2004-05-10
申请号：NO20040987
申请日：2004-03-08
Applicant: CELLTECH R&D LTD
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C07K16/28 , C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C07K16/46 , C12N15/70 , G01N33/577
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565
-
公开(公告)号：CA2458464A1
公开(公告)日：2003-04-17
申请号：CA2458464
申请日：2002-10-10
Applicant: CELLTECH R&D LTD
Inventor： TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , POPPLEWELL ANDREW GEORGE , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , A61K47/30 , C12N15/70
Abstract: There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicat ed.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.022 seconds)
